MMCB plans to release an additional series

The management of the biotechnology company Hemabank is currently studying options for an additional placement of ordinary shares through an open subscription. The possible volume of the new issue will reach 3.3 million shares. The final value will be determined later based on the average market indicators of previous trading sessions. The shareholders plan to make a final decision on all aspects of the procedure at the general meeting on April 7, 2026.